TACSTD2
Protein-coding gene in the species Homo sapiens
From Wikipedia, the free encyclopedia
TACSTD2 is a human gene that encodes tumor-associated calcium signal transducer 2 (Trop-2, or epithelial glycoprotein-1 antigen (EGP-1))[5] is a .[6][7][8]
This intronless gene is located at the short arm of chromosome 1 (1p32.1).[9] It encodes a carcinoma-associated antigen defined by the monoclonal antibody GA733. This antigen is a member of a family including at least two type I membrane proteins. It transduces an intracellular calcium signal and acts as a cell surface receptor.
Mutations of this gene result in gelatinous drop-like corneal dystrophy, an autosomal recessive disorder characterized by severe corneal amyloidosis leading to blindness.[8]
Trop-2
Trop-2 expression was originally described in trophoblasts (placenta) and fetal tissues (e.g., lung). Later, its expression was described in the normal stratified squamous epithelium of the skin, uterine cervix, esophagus, and tonsillar crypts.[10]
Trop-2 plays a role in tumor progression by interacting with molecular signaling pathways traditionally associated with cancer development and progression. Aberrant overexpression of Trop-2 has been described in several solid cancers, such as colorectal, renal, lung, and breast cancers. Trop-2 expression has been described in some rare and aggressive malignancies, e.g., salivary duct, anaplastic thyroid, uterine/ovarian, and neuroendocrine prostate cancers.[10] This overexpression is caused by deregulation at a transcriptional and posttranscriptional level.[9]
Trop-2 causes cancer cell growth, proliferation, invasion, migration, and survival of cancer cells. Trop-2 is associated with tumor aggressiveness and poor prognosis. Tumor cell proliferation is disturbed when Trop-2 is knocked down. Trop-2 is a possible prognostic biomarker to identify high-risk patients, as well as an attractive therapeutic target for late-stage disease.[9]
Therapeutics
This antigen is the target of antibody-drug conjugates sacituzumab govitecan, datopotamab deruxtecan (Dato-DXd), and sacituzumab tirumotecan.[11] In May 2026, Merck announced that its Phase 3 sacituzumab tirumotecan TroFuse-005 trial met both primary endpoints (overall survival + progression-free survival) in patients with advanced or recurrent endometrial cancer who had progressed after platinum chemotherapy and immunotherapy. it has Breakthrough Therapy Designation for EGFR-mutated NSCLC.[12]
